{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:45:22Z","timestamp":1792028722236,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00259-024-06803-w","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T05:01:46Z","timestamp":1719032506000},"page":"3496-3500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Neuroimaging biomarkers in the biological definition of Parkinson\u2019s disease and dementia with Lewy bodies \u2013 EANM position on current state, unmet needs and future perspectives"],"prefix":"10.1007","volume":"51","author":[{"given":"Matthias","family":"Brendel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Yakushev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelleke","family":"Tolboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Verger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie L.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Aguiar","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fraioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Traub-Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatienne","family":"Van Weehaeghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Barthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"issue":"2","key":"6803_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger GU, et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23(2):191\u2013204.","journal-title":"Lancet Neurol"},{"issue":"2","key":"6803_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178\u201390.","journal-title":"Lancet Neurol"},{"issue":"2","key":"6803_CR3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2967\/jnumed.123.266191","volume":"65","author":"JP Seibyl","year":"2024","unstructured":"Seibyl JP. \u03b1-synuclein seeding amplification assay: a breakthrough in diagnosing Parkinson disease? J Nucl Med. 2024;65(2):174\u20135.","journal-title":"J Nucl Med"},{"issue":"5","key":"6803_CR4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/mds.28984","volume":"37","author":"OM Alzghool","year":"2022","unstructured":"Alzghool OM, et al. alpha-synuclein radiotracer development and in vivo imaging: recent advancements and new perspectives. Mov Disord. 2022;37(5):936\u201348.","journal-title":"Mov Disord"},{"issue":"16","key":"6803_CR5","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","volume":"186","author":"J Xiang","year":"2023","unstructured":"Xiang J, et al. Development of an alpha-synuclein positron emission tomography tracer for imaging synucleinopathies. Cell. 2023;186(16):3350-3367 e19.","journal-title":"Cell"},{"issue":"1","key":"6803_CR6","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith R, et al. The alpha-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat Commun. 2023;14(1):6750.","journal-title":"Nat Commun"},{"issue":"4","key":"6803_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/s00259-022-06069-0","volume":"50","author":"F Lanfranchi","year":"2023","unstructured":"Lanfranchi F, et al. Different z-score cut-offs for striatal binding ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson\u2019s Disease (PD) and dementia with Lewy bodies (DLB). Eur J Nucl Med Mol Imaging. 2023;50(4):1090\u2013102.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6803_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13550-020-00727-w","volume":"10","author":"S Morbelli","year":"2020","unstructured":"Morbelli S, et al. Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools. EJNMMI Res. 2020;10(1):137.","journal-title":"EJNMMI Res"},{"issue":"8","key":"6803_CR9","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","volume":"47","author":"S Morbelli","year":"2020","unstructured":"Morbelli S, et al. EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47(8):1885\u2013912.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6803_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13550-018-0450-0","volume":"8","author":"S Jakobson Mo","year":"2018","unstructured":"Jakobson Mo S, et al. Dopamine transporter imaging with [(18)F]FE-PE2I PET and [(123)I]FP-CIT SPECT-a clinical comparison. EJNMMI Res. 2018;8(1):100.","journal-title":"EJNMMI Res"},{"issue":"2","key":"6803_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/brain\/119.2.585","volume":"119","author":"P Morrish","year":"1996","unstructured":"Morrish P, Sawle G, Brooks D. An [18F] dopa\u2013PET and clinical study of the rate of progression in Parkinson\u2019s disease. Brain. 1996;119(2):585\u201391.","journal-title":"Brain"},{"issue":"14","key":"6803_CR12","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/mds.25975","volume":"29","author":"J Kraemmer","year":"2014","unstructured":"Kraemmer J, et al. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord. 2014;29(14):1767\u201373.","journal-title":"Mov Disord"},{"issue":"11","key":"6803_CR13","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.2967\/jnumed.119.239418","volume":"61","author":"DD Maltais","year":"2020","unstructured":"Maltais DD, et al. Confirmation of (123)I-FP-CIT SPECT quantification methods in dementia with Lewy bodies and other neurodegenerative disorders. J Nucl Med. 2020;61(11):1628\u201335.","journal-title":"J Nucl Med"},{"key":"6803_CR14","doi-asserted-by":"publisher","first-page":"fcad021","DOI":"10.1093\/braincomms\/fcad021","volume":"5","author":"P Diaz-Galvan","year":"2023","unstructured":"Diaz-Galvan P, et al. Brain glucose metabolism and nigrostriatal degeneration in isolated rapid eye movement sleep behaviour disorder. Brain Commun. 2023;5:fcad021. https:\/\/doi.org\/10.1093\/braincomms\/fcad021.","journal-title":"Brain Commun"},{"issue":"1","key":"6803_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1-15.e1-4.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"6803_CR16","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s00259-010-1491-4","volume":"37","author":"A Flotats","year":"2010","unstructured":"Flotats A, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37(9):1802\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"6803_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/ehjci\/jeab007","volume":"22","author":"A Gimelli","year":"2021","unstructured":"Gimelli A, et al. The role of myocardial innervation imaging in different clinical scenarios: an expert document of the European Association of Cardiovascular Imaging and Cardiovascular Committee of the European Association of Nuclear Medicine. Eur Heart J Cardiovasc Imaging. 2021;22(5):480\u201390.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"7","key":"6803_CR18","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/mds.23659","volume":"26","author":"AE King","year":"2011","unstructured":"King AE, Mintz J, Royall DR. Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord. 2011;26(7):1218\u201324.","journal-title":"Mov Disord"},{"issue":"1","key":"6803_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40658-019-0250-2","volume":"6","author":"J Brumberg","year":"2019","unstructured":"Brumberg J, et al. Imaging cardiac sympathetic innervation with MIBG: linear conversion of the heart-to-mediastinum ratio between different collimators. EJNMMI Phys. 2019;6(1):12.","journal-title":"EJNMMI Phys"},{"issue":"10","key":"6803_CR20","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/ene.13728","volume":"25","author":"F Nobili","year":"2018","unstructured":"Nobili F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018;25(10):1201\u201317.","journal-title":"Eur J Neurol"},{"issue":"4","key":"6803_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"6803_CR22","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00259-021-05603-w","volume":"49","author":"E Guedj","year":"2022","unstructured":"Guedj E, et al. EANM procedure guidelines for brain PET imaging using [(18)F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49(2):632\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"6803_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1474-4422(10)70002-8","volume":"9","author":"CC Tang","year":"2010","unstructured":"Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010;9(2):149\u201358. https:\/\/doi.org\/10.1016\/S1474-4422(10)70002-8.","journal-title":"Lancet Neurol."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06803-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06803-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06803-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T05:28:59Z","timestamp":1727760539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06803-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["6803"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06803-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"22 June 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable to this Editorial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"MB received consulting\/speaker honoraria from Life Molecular Imaging, GE healthcare, and Roche, and reader honoraria from Life Molecular Imaging. HB received consulting\/speaker honoraria from Hermes Medical Solutions, IBA, Lilly, Eisai and Novartis\/AAA, reader honoraria from Life Molecular Imaging, and dosing committee honoraria from Pharmtrace. The other authors declare no conflict of interest.NLA has received honoraria for consultation or advisory board participation from Novartis, Advanced Accelerator Applications, Servier and Telix Pharmaceuticals, honoraria for lectures from OncLive, and research funding from Novocure.IY received speaker honoraria from Piramal and consultant fees from ABX-CRO, Blue Earth Diagnostics, and Pentixapharm.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}